The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study

被引:0
作者
Akito Nozaki
Masanori Atsukawa
Chisa Kondo
Hidenori Toyoda
Makoto Chuma
Makoto Nakamuta
Haruki Uojima
Koichi Takaguchi
Hiroki Ikeda
Tsunamasa Watanabe
Shintaro Ogawa
Norio Itokawa
Taeang Arai
Atsushi Hiraoka
Toru Asano
Shinichi Fujioka
Tadashi Ikegami
Toshihide Shima
Chikara Ogawa
Takehiro Akahane
Noritomo Shimada
Shinya Fukunishi
Hiroshi Abe
Akihito Tsubota
Takuya Genda
Hironao Okubo
Shigeru Mikami
Asahiro Morishita
Akio Moriya
Joji Tani
Yoshihiko Tachi
Naoki Hotta
Toru Ishikawa
Takeshi Okanoue
Yasuhito Tanaka
Takashi Kumada
Katsuhiko Iwakiri
Shin Maeda
机构
[1] Yokohama City University Medical Center,Gastroenterological Center
[2] Nippon Medical School,Department of Internal Medicine, Division of Gastroenterology and Hepatology
[3] Ogaki Municipal Hospital,Department of Gastroenterology
[4] National Hospital Organization Kyushu Medical Center,Department of Gastroenterology, Internal Medicine
[5] Kitasato University School of Medicine,Department of Hepatology
[6] Kagawa Prefectural Central Hospital,Department of Internal Medicine
[7] St. Marianna University School of Medicine,Department of Virology and Liver Unit
[8] Nagoya City University,Division of Gastroenterology, Department of Internal Medicine
[9] Graduate School of Medical Sciences,Division of Gastroenterology, Department of Internal Medicine
[10] Nippon Medical School Chiba Hokusoh Hospital,Gastroenterology Center
[11] Nippon Medical School Musashikosugi Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine
[12] Ehime Prefectural Central Hospital,Department of Gastroenterology
[13] Tokyo Metropolitan Bokutoh Hospital,Department of Gastroenterology and Hepatology
[14] Okayama Saiseikai General Hospital,Department of Gastroenterology and Hepatology
[15] Tokyo Medical University Ibaraki Medical Center,Department of Gastroenterology
[16] Saiseikai Suita Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine
[17] Takamatsu Red Cross Hospital,Second Department of Internal Medicine
[18] Japanese Red Cross Ishinomaki Hospital,Division of Gastroenterology and Hepatology, Department of Internal Medicine
[19] Otakanomori Hospital,Core Research Facilities for Basic Science
[20] Osaka Medical College,Department of Gastroenterology
[21] Shinmatsudo Central General Hospital,Department of Gastroenterology
[22] The Jikei University School of Medicine,Division of Gastroenterology, Department of Internal Medicine
[23] Juntendo Shizuoka University Hospital,Department of Gastroenterology
[24] Juntendo Nerima University Hospital,Department of Gastroenterology
[25] Kikkoman General Hospital,Department of Internal Medicine
[26] Kagawa University Graduate School of Medicine,Division of Hepatology, Department of Internal Medicine
[27] Mitoyo General Hospital,Department of Hepatology
[28] Yashima General Hospital,Department of Gastroenterology
[29] Bantane Hospital,undefined
[30] Fujita Health University School of Medicine,undefined
[31] Masuko Memorial Hospital,undefined
[32] Saiseikai Niigata Daini Hospital,undefined
[33] Yokohama City University Graduate School of Medicine,undefined
来源
Hepatology International | 2020年 / 14卷
关键词
Glecaprevir; Pibrentasvir; Chronic hepatitis C; Refractory factors; Multicenter study;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:225 / 238
页数:13
相关论文
共 50 条
[21]   Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study [J].
Su, Pei-Yuan ;
Chen, Yang-Yuan ;
Lai, Jun-Hung ;
Chen, Hung-Ming ;
Yao, Chih-Ta ;
Liu, I-Ling ;
Zeng, Ya-Huei ;
Huang, Siou-Ping ;
Hsu, Yu-Chun ;
Wu, Shun-Sheng ;
Siao, Fu-Yuan ;
Yen, Hsu-Heng .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (22)
[22]   The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort [J].
Yaras, Serkan ;
Demir, Mehmet ;
Barutcu, Sezgin ;
Yildirim, Abdullah Emre ;
Gurel, Selim ;
Ucbilek, Enver ;
Kurtulmus, Ilkce Akgun ;
Kayhan, Meral Akdogan ;
Vatansever, Sezgin ;
Adanir, Haydar ;
Danis, Nilay ;
Duman, Serkan ;
Turan, Ilker ;
Ari, Derya ;
Kose, Sukran ;
Alkim, Huseyin ;
Harputluoglu, Muhsin Murat ;
Dilber, Feyza ;
Akyildiz, Murat ;
Cosar, Arif Mansur ;
Durak, Serdar ;
Sirin, Goktug ;
Kefeli, Ayse ;
Gokcan, Hale ;
Avcioglu, Ufuk ;
Ayyildiz, Talat ;
Sezgin, Orhan ;
Akarsu, Mesut ;
Dincer, Dinc ;
Guzelbulut, Fatih ;
Gunsar, Fulya ;
Akarca, Ulus Salih ;
Idilman, Ramazan .
HEPATOLOGY FORUM, 2023, 4 (03) :92-96
[23]   A real-world clinical application of the combination therapy with glecaprevir/pibrentasvir to special population in chronic hepatitis C patients [J].
Sato, Ken ;
Yamazaki, Yuichi ;
Kobayashi, Takeshi ;
Tojima, Hiroaki ;
Horiguchi, Norio ;
Kakizaki, Satoru ;
Uraoka, Toshio ;
Ohnishi, Hiroshi ;
Okamoto, Hiroaki .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 :444-444
[24]   Real-life Data of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients: A Single-center Study [J].
Cabalak, Mehmet ;
Bal, Tayibe ;
Ocak, Sabahattin ;
Bal, Isa Ahmet ;
Onlen, Yusuf .
HEPATITIS MONTHLY, 2023, 23 (01)
[25]   Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients [J].
Margusino-Framinan, Luis ;
Cid-Silva, Purificacion ;
Rotea-Salvo, Sandra ;
Mena-de-Cea, Alvaro ;
Suarez-Lopez, Francisco ;
Vazquez-Rodriguez, Pilar ;
Delgado-Blanco, Manuel ;
Sanclaudio-Luhia, Ana Isabel ;
Martin-Herranz, Isabel ;
Castro-Iglesias, Angeles .
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (E1) :E41-E47
[26]   Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study [J].
Beisel, Claudia ;
Herrmann, Marissa ;
Piecha, Felix ;
Lampalzer, Sibylle ;
Buescher, Gustav ;
Pischke, Sven ;
Wiesch, Julian Schulze zur .
HEPATITIS MONTHLY, 2021, 21 (01)
[27]   Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older [J].
Foster, Graham R. ;
Asselah, Tarik ;
Kopecky-Bromberg, Sarah ;
Lei, Yang ;
Asatryan, Armen ;
Trinh, Roger ;
Zadeikis, Neddie ;
Mensa, Federico J. .
PLOS ONE, 2019, 14 (01)
[28]   Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital [J].
Ruwayni, Ali A. ;
Alobary, Eman E. ;
Alyahya, Khalid M. .
SAUDI MEDICAL JOURNAL, 2024, 45 (01) :34-39
[29]   Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R) [J].
Cornberg, Markus ;
Stoehr, Albrecht ;
Naumann, Uwe ;
Teuber, Gerlinde ;
Klinker, Hartwig ;
Lutz, Thomas ;
Moller, Hjoerdis ;
Hidde, Dennis ;
Lohmann, Kristina ;
Simon, Karl-Georg .
VIRUSES-BASEL, 2022, 14 (07)
[30]   Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment [J].
Liu, Chen-Hua ;
Yang, Sheng-Shun ;
Peng, Cheng-Yuan ;
Lin, Woan-Tyy ;
Liu, Chun-Jen ;
Su, Tung-Hung ;
Tseng, Tai-Chung ;
Chen, Pei-Jer ;
Chen, Ding-Shinn ;
Kao, Jia-Horng .
JOURNAL OF VIRAL HEPATITIS, 2020, 27 (06) :568-575